|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 6.14 Billion
|
|
Market Size (2030)
|
USD 8.20 Billion
|
|
CAGR (2025-2030)
|
4.92%
|
|
Fastest Growing Segment
|
Acute Respiratory Diseases
|
|
Largest Market
|
North America
|
Market Overview
Global Corticosteroids Market was valued
at USD 6.14 Billion in 2024 and is expected to reach USD 8.20 Billion in the
forecast period with a CAGR of 4.92% through 2030. The Global Corticosteroids
Market has experienced significant growth over the years due to the increasing
prevalence of chronic inflammatory and autoimmune disorders, such as asthma,
arthritis, and dermatitis. These conditions require long-term management, and
corticosteroids are commonly prescribed as part of the treatment regimen due to
their ability to reduce inflammation and modulate immune responses. The rising
awareness about the benefits of corticosteroids in treating a range of
conditions has further contributed to their widespread use, leading to an
increase in demand. Moreover, the market is witnessing the development of new
corticosteroid formulations that offer improved efficacy and reduced side
effects, which appeals to both patients and healthcare providers.
A key trend in the market is the growing
adoption of combination therapies that incorporate corticosteroids. These
therapies aim to improve treatment outcomes and reduce the need for higher
doses of corticosteroids, which can have adverse long-term effects. With the
rise of chronic diseases, especially among the aging population, the demand for
more advanced, targeted corticosteroid treatments continues to increase. The
market is also benefiting from the rising focus on personalized medicine, as
tailored corticosteroid treatments can offer better efficacy for patients with
specific needs, such as those with rare autoimmune diseases or conditions that
involve complex inflammation mechanisms. The integration of digital health
technologies also supports better patient monitoring, ensuring more precise and
effective use of corticosteroid treatments.
Despite the positive growth outlook, the
Global Corticosteroids Market faces several challenges. The long-term use of
corticosteroids is associated with potential side effects, including weight
gain, osteoporosis, and increased susceptibility to infections, which may deter
patients from adhering to treatment regimens. There is also increasing concern
regarding the over-prescription of corticosteroids, which may lead to
unnecessary side effects. Furthermore, the market faces regulatory hurdles
related to the approval of new corticosteroid drugs, particularly in the areas
of safety and efficacy, which can delay the launch of new products. The cost of
corticosteroid therapies, especially for long-term treatments, may also be a
challenge, as healthcare systems look for cost-effective alternatives to manage
chronic diseases. Despite these challenges, the demand for corticosteroids is
expected to remain strong, driven by the ongoing need for effective treatments
for inflammatory and autoimmune conditions.
Key Market Drivers
Rising
Incidence of Chronic Inflammatory Diseases
The rising incidence of chronic
inflammatory diseases is a significant driver for the Global Corticosteroids
Market. Conditions such as rheumatoid arthritis, inflammatory bowel disease
(IBD), and psoriasis are becoming increasingly prevalent worldwide. For
instance, a study published in The Lancet in 2021 reported that
the global prevalence of IBD increased from 3.32 million cases in 1990 to 4.90
million cases in 2019, marking a 47.45% rise over this period.
Similarly, the Centers for Disease
Control and Prevention (CDC) reported that approximately 53.2 million U.S.
adults aged 18 years and older had diagnosed arthritis between 2019 and 2021,
with an age-standardized prevalence of 18.7%.
The increasing prevalence of these
chronic inflammatory conditions is driven by factors such as aging populations,
lifestyle changes, and environmental influences. As the global population ages,
the incidence of age-related inflammatory diseases rises. Lifestyle factors,
including sedentary behavior and poor dietary habits, contribute to the
development of conditions like rheumatoid arthritis and IBD. Environmental
factors, such as pollution and smoking, also play a role in the onset of these
diseases.
Corticosteroids are widely prescribed to
manage these conditions due to their potent anti-inflammatory properties. They
help reduce inflammation, alleviate symptoms, and improve the quality of life
for patients. The growing burden of chronic inflammatory diseases is expected
to drive the demand for corticosteroid therapies, thereby propelling market
growth. In summary, the rising incidence of chronic inflammatory diseases,
driven by demographic and lifestyle factors, is a key factor propelling the
growth of the Global Corticosteroids Market. The increasing prevalence of these
conditions underscores the need for effective treatments, with corticosteroids
playing a central role in their management.
Advancements
in Drug Delivery Systems
Advancements in drug delivery systems are a key driver
in the growth of the Global Corticosteroids Market. The evolution of drug
delivery technologies, particularly for corticosteroids, has significantly
improved treatment outcomes, patient compliance, and the overall effectiveness
of corticosteroid therapies. Inhalers and nebulizers for respiratory
conditions, such as asthma and COPD, have seen major improvements in terms of
efficiency, ease of use, and precision in delivering the correct dose of
medication directly to the lungs. These innovations have made corticosteroid
treatments more targeted and effective, reducing systemic side effects and
increasing their therapeutic benefits.
The development of advanced formulations such as dry
powder inhalers (DPIs), metered-dose inhalers (MDIs), and combination inhalers
has expanded the range of corticosteroid treatment options, making them more
accessible and effective for a wider population. Additionally, the introduction
of sustained-release formulations for oral corticosteroids has improved patient
compliance by reducing the frequency of administration and minimizing side
effects, which are often associated with long-term use.
Injectable corticosteroids are also benefiting from
advancements in drug delivery systems, with innovations in controlled release
injectables, reducing the frequency of administration and offering better
management of conditions like rheumatoid arthritis and autoimmune diseases.
These advancements are not only improving the overall patient experience but
also helping clinicians manage chronic conditions more efficiently. As these
drug delivery systems continue to evolve, they will likely drive further growth
in the corticosteroids market, particularly in emerging markets where access to
advanced treatments is increasing.
Government
Initiatives and Healthcare Infrastructure Improvements
Government initiatives and improvements
in healthcare infrastructure are pivotal drivers fueling the growth of the
Global Corticosteroids Market. In recent years, many governments worldwide have
focused on strengthening healthcare systems and enhancing access to essential
treatments, such as corticosteroids, especially in regions where chronic
diseases like asthma, autoimmune disorders, and dermatological conditions are
prevalent. For instance, India's Economic Survey 2023 reported a
significant increase in government expenditure on healthcare, with the budgeted
share of the health sector in the GDP rising to 2.1% in fiscal year 2022-23,
compared to 1.6% in 2020-21. This growth in healthcare spending
highlights the government's commitment to improving healthcare infrastructure
and making treatments, including corticosteroids, more accessible to the
general population.
Furthermore, the Ministry of
Health and Family Welfare in India released the "Health Dynamics of India
(Infrastructure and Human Resources) 2022-23" report, which underscores
significant advancements in healthcare infrastructure. As of March 31, 2023,
India had a total of 1,69,615 Sub-Centres, 31,882 Primary Health Centres, 6,359
Community Health Centres, 1,340 Sub-Divisional/District Hospitals, and 362
Medical Colleges. This robust healthcare infrastructure has helped in
providing broader access to corticosteroid treatments, particularly in rural
and underserved regions, which were previously underserved in terms of medical
resources.
Such government-driven investments in
healthcare systems and infrastructure not only make treatments more accessible
but also support efforts to improve the diagnosis and treatment of chronic
conditions, driving the demand for corticosteroids. These initiatives are
helping reduce healthcare disparities, enhancing patient access to life-saving
treatments, and facilitating broader market penetration. As these programs
continue to grow, they will significantly contribute to the sustained expansion
of the corticosteroids market globally.
Download Free Sample Report
Key Market Challenges
Adverse
Side Effects of Long-Term Use
The adverse side effects of long-term use of
corticosteroids represent a significant challenge for the Global
Corticosteroids Market. While corticosteroids are highly effective in treating
a variety of conditions such as respiratory diseases, autoimmune disorders, and
dermatological conditions, their prolonged use can lead to a range of health
complications. These side effects include osteoporosis, weight gain, high blood
pressure, diabetes, cataracts, and an increased risk of infections due to the
immunosuppressive nature of corticosteroids. Such adverse effects can deter
patients and healthcare providers from opting for long-term corticosteroid
therapies, limiting their use to only necessary cases or short durations.
Patients who require long-term corticosteroid
treatment often face a trade-off between managing their condition and coping
with the side effects. This dilemma can affect treatment adherence and patient
outcomes, leading to a reduction in the demand for corticosteroid medications
in certain markets. Healthcare professionals also have to balance the benefits
of corticosteroids with the potential risks, making them cautious when
prescribing these drugs for chronic conditions. Furthermore, regulatory bodies
are increasingly scrutinizing the safety profiles of medications, including
corticosteroids, pushing pharmaceutical companies to invest in research to
develop safer alternatives or better formulations with fewer side effects. This
challenge is leading to the development of novel corticosteroid derivatives or
alternative therapies that aim to reduce the adverse effects associated with
long-term use. As awareness about these risks grows among both patients and
physicians, it is expected to impact the growth of the corticosteroid market
and encourage the search for better treatment options.
Increasing
Regulatory Scrutiny and Approval Delays
Increasing regulatory scrutiny and approval delays are
significant challenges facing the Global Corticosteroids Market. Regulatory
bodies such as the U.S. Food and Drug Administration (FDA), European Medicines
Agency (EMA), and others have stringent requirements for the approval of new
corticosteroid products and formulations. These include extensive clinical
trial data, safety profiles, and evidence of therapeutic efficacy, which often
result in lengthy and costly approval processes. As the market sees a rise in
the development of new corticosteroid therapies, especially those targeting
specific conditions or offering novel delivery mechanisms, the regulatory
process has become more complex and time-consuming.
Approval delays can lead to significant revenue losses
for companies that rely on timely market entry of their products. Any delay in
obtaining regulatory approval may cause a product to miss key market
opportunities, particularly when competing treatments are already available.
The extended timelines also increase the costs associated with research and
development, further raising the financial burden on companies in the
corticosteroid market.
In addition, the evolving regulatory landscape around
drug safety, manufacturing practices, and quality control is adding another
layer of complexity. Regulatory bodies are becoming more focused on ensuring
that corticosteroid products meet high standards, particularly regarding their
long-term safety profiles. As a result, companies must invest more resources in
complying with these evolving standards, which can slow down the development
and commercialization of corticosteroids, hindering the market's growth. This
increased scrutiny and approval delays create significant barriers for both new
and existing players in the market, affecting their competitive position.
Key Market Trends
Integration
of Biologics with Corticosteroids
The integration of biologics with corticosteroids is a
significant trend shaping the Global Corticosteroids Market. Biologics,
particularly monoclonal antibodies, have emerged as a complementary treatment
for various autoimmune and inflammatory conditions, often used in combination
with corticosteroids to enhance therapeutic outcomes. This combination approach
is particularly evident in the treatment of conditions such as rheumatoid
arthritis, psoriasis, and asthma, where corticosteroids are effective in managing
inflammation, while biologics target the underlying immune response.
In diseases like rheumatoid arthritis, biologics have
shown the potential to modify the disease process, providing long-term
benefits, while corticosteroids remain a go-to treatment for managing acute
flare-ups. By combining these two treatment options, patients experience
improved disease control and reduced symptom severity. The combination approach
also helps mitigate the side effects associated with long-term corticosteroid
use, such as osteoporosis and weight gain, by allowing for lower corticosteroid
doses.
This integration is gaining momentum as clinical
studies continue to demonstrate the efficacy of biologic and corticosteroid
combinations in improving patient outcomes. For instance, a study
published in the American Journal of Clinical Dermatology highlights that
combining biologic agents with traditional therapies, such as methotrexate, can
provide improved therapeutic options for patients who inadequately respond to a
single drug or when efficacy may be increased with supplementation of another
treatment.
Pharmaceutical companies are increasingly investing in
research to develop combination therapies that incorporate biologics and
corticosteroids, offering better-targeted treatments with fewer side effects.
This trend is expected to grow as healthcare providers aim to provide
personalized, more effective therapies, especially for chronic diseases where
long-term management is essential. The continued evolution of combination
therapies represents a promising frontier in corticosteroid treatment,
contributing to market growth and offering patients more effective, sustainable
solutions for managing chronic inflammatory conditions.
Increasing
Adoption of Combination Therapies
The increasing adoption of combination therapies is a
prominent trend in the Global Corticosteroids Market, driven by the need for
more effective and tailored treatments for complex conditions such as asthma,
rheumatoid arthritis, and chronic obstructive pulmonary disease (COPD).
Combination therapies involve using corticosteroids in conjunction with other
medications, such as bronchodilators, biologics, or disease-modifying
antirheumatic drugs (DMARDs), to provide enhanced therapeutic benefits. For instance,
in asthma treatment, corticosteroids are often paired with long-acting
beta-agonists (LABAs) to improve lung function and reduce inflammation,
resulting in better symptom control and fewer exacerbations.
This trend has gained significant momentum as
healthcare providers recognize the value of combination treatments in managing
chronic inflammatory conditions more effectively. By combining corticosteroids
with other drug classes, the goal is to achieve a synergistic effect, where the
benefits of both drugs are amplified, allowing for lower doses of
corticosteroids while maintaining or improving treatment efficacy. This reduces
the potential for side effects, which are a concern with long-term corticosteroid
use, such as osteoporosis and weight gain.
The adoption of combination therapies is supported by
advancements in drug formulation technologies that allow for more convenient,
fixed-dose combinations, improving patient adherence and convenience. As the
demand for personalized medicine grows, pharmaceutical companies are
increasingly focused on developing combination therapies that target multiple
pathways of disease progression simultaneously. These therapies are expected to
dominate in treating conditions that require long-term management, offering improved
outcomes and better quality of life for patients. The rising preference for
combination therapies is poised to drive growth in the corticosteroids market,
offering more comprehensive and sustainable treatment options.
Segmental Insights
Type
Insights
Based
on the Type, Glucocorticoids emerged as the dominant segment in the Global
Corticosteroids Market in 2024. This is due to their widespread use in the
treatment of a variety of chronic and acute conditions, including autoimmune
diseases, asthma, and inflammatory disorders. These corticosteroids are
primarily used for their potent anti-inflammatory and immunosuppressive
properties, making them the first-line treatment for conditions such as
rheumatoid arthritis, lupus, and multiple sclerosis. Their ability to provide
rapid symptom relief and control inflammation is a major factor driving their
dominance in the market. Moreover, glucocorticoids are available in a variety
of formulations, including oral, topical, and injectable forms, offering
flexibility in treatment options. This versatility allows healthcare providers
to tailor treatments to the specific needs of patients, further bolstering
their market share. The global prevalence of chronic inflammatory conditions
and autoimmune diseases is rising, contributing to the growing demand for
glucocorticoid therapies. Their effectiveness in managing conditions like
asthma, COPD, and skin allergies further supports their widespread use. Despite
concerns over long-term side effects such as weight gain, osteoporosis, and
increased risk of infections, the benefits of glucocorticoids in managing acute
flare-ups and chronic diseases continue to make them a dominant choice in
corticosteroid therapies. This broad utility and established clinical efficacy
are key reasons for their leading position in the market.
Route
of Administration Insights
Based on the Route of Administration, Topical
emerged
as the dominant segment in the
Global Corticosteroids Market in 2024. This is due to their targeted
and effective treatment for various dermatological conditions, such as eczema,
psoriasis, and dermatitis. These medications are applied directly to the skin,
offering localized relief with fewer systemic side effects compared to oral or
injectable corticosteroids. This makes topical corticosteroids a preferred
choice for patients and healthcare providers when treating skin-related
inflammatory conditions. The growing prevalence of skin disorders worldwide,
including allergic skin reactions, acne, and inflammatory skin diseases, is
contributing to the increasing demand for topical corticosteroids. Their
ability to reduce inflammation, redness, and itching associated with these
conditions makes them highly effective and widely prescribed. Furthermore, the
availability of various strengths, formulations (creams, ointments, lotions),
and packaging options allows healthcare providers to select the most
appropriate treatment based on the severity and location of the condition. Topical
corticosteroids are also favored for their ease of use, allowing patients to
apply the medication themselves at home, which enhances patient compliance and
treatment outcomes. As patients and healthcare providers increasingly seek
treatments that minimize the risk of systemic side effects while effectively
managing skin conditions, topical corticosteroids remain the dominant and
preferred route of administration in the corticosteroids market.
Download Free Sample Report
Regional Insights
North America emerged
as the dominant region in the Global Corticosteroids Market in 2024. This is due to several key factors,
including high healthcare expenditure, a well-established healthcare
infrastructure, and a large patient population suffering from chronic
conditions such as asthma, arthritis, and autoimmune diseases. The region has a
robust demand for corticosteroids, driven by the high prevalence of
inflammatory disorders, respiratory diseases, and skin conditions that require
long-term management with corticosteroid medications. The United States, in
particular, is the largest market for corticosteroids due to its advanced
healthcare system, access to cutting-edge treatments, and a large number of
pharmaceutical companies developing and marketing corticosteroid drugs.
Government programs, such as Medicare and Medicaid, further support the
affordability and accessibility of corticosteroid treatments, contributing to
their widespread use. North America’s well-developed regulatory framework
ensures that new corticosteroid treatments are rigorously tested and approved,
promoting innovation in the field. The growing adoption of combination
therapies, which often include corticosteroids, also drives market growth in
the region. With increasing awareness of chronic conditions and advancements in
treatment options, North America remains the dominant region in the global
corticosteroids market, supported by a combination of healthcare policies,
patient demand, and innovation in therapeutic options.
Recent Developments
- In December 2024, Neurocrine Biosciences
received FDA approval for Crenessity, a groundbreaking treatment for congenital
adrenal hyperplasia (CAH) that provides a new alternative to long-term
glucocorticoid therapy, which can result in severe side effects. Crenessity is
suitable for both adults and children as young as four, addressing hormone
imbalances caused by CAH. Neurocrine intends to launch the drug shortly after
approval, with approximately 30,000 CAH patients in the U.S. The drug is
projected to have an annual net price of USD 264,784, with global peak sales
expected to reach USD 1.47 billion by 2030.
- In September 2024, AstraZeneca’s FASENRA
(benralizumab) received FDA approval for treating adult patients with
eosinophilic granulomatosis with polyangiitis (EGPA), a rare and potentially
fatal immune-mediated vasculitis. This approval was based on positive results
from the MANDARA Phase III trial, published in The New England Journal of
Medicine, which compared the efficacy and safety of FASENRA with mepolizumab,
the only approved EGPA treatment.
- In June 2024, Sun Pharmaceutical
Industries Ltd. completed the acquisition of Taro Pharmaceutical Industries
Ltd. to enhance its position in the pharmaceutical market, particularly within
the off-patent drug and over-the-counter sectors. Taro, a research-focused
pharmaceutical manufacturer, also produces corticosteroid products.
- In March 2024, Agamree (vamorolone)
became available for Duchenne muscular dystrophy (DMD) patients aged 2 and
above in the U.S., distributed through a specialized pharmacy network. The U.S.
Food and Drug Administration (FDA) granted approval for this next-generation
steroid in October 2023, noting its anticipated improved tolerability compared
to traditional DMD corticosteroids. Catalyst Pharmaceuticals, which secured the
North American rights to the drug from Santhera prior to its approval, will
handle the marketing of Agamree.
Key Market Players
- AbbVie
Inc.
- AstraZeneca
plc
- Bayer
AG
- Eli
Lilly and Company
- F.
Hoffmann-La Roche Ltd.
- GlaxoSmithKline
plc
- Merck
& Co., Inc.
- Novartis
International AG
- Pfizer
Inc.
- Sanofi
S.A.
|
By Type
|
By Route of Administration
|
By Application
|
By Region
|
- Glucocorticoids
- Mineralocorticoids
|
- Inhaled
- Topical
- Injectable
- Oral
|
- Skin Allergies
- Gastroenterology
- Endocrinology
- Acute Respiratory Diseases
- Rheumatology Indications
- Others
|
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
|
Report Scope:
In this report, the Global Corticosteroids
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- Corticosteroids
Market,
By Type:
o
Glucocorticoids
o
Mineralocorticoids
- Corticosteroids
Market,
By Route of Administration:
o
Inhaled
o
Topical
o
Injectable
o
Oral
- Corticosteroids
Market,
By Application:
o
Skin
Allergies
o
Gastroenterology
o
Endocrinology
o
Acute
Respiratory Diseases
o
Rheumatology
Indications
o
Others
- Corticosteroids
Market, By Region:
o
North
America
§
United
States
§
Canada
§
Mexico
o
Europe
§
France
§
United
Kingdom
§
Italy
§
Germany
§
Spain
o
Asia-Pacific
§
China
§
India
§
Japan
§
Australia
§
South
Korea
o
South
America
§
Brazil
§
Argentina
§
Colombia
o
Middle
East & Africa
§
South
Africa
§
Saudi
Arabia
§
UAE
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in the Global Corticosteroids Market.
Available Customizations:
Global Corticosteroids Market report with the given market data,
TechSci Research offers customizations according to a company's specific needs.
The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to
five).
Global Corticosteroids Market is an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at [email protected]